Molecular Mechanisms of Chemoresistance in Gastric Cancer

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2016 Sep 28

PMID 27672425

Citations 73

Authors

Wen-Jia Shi

Jin-Bo Gao

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is the fourth most common cancer and the second leading cause of cancer deaths worldwide. Chemotherapy is one of the major treatments for gastric cancer, but drug resistance limits the effectiveness of chemotherapy, which results in treatment failure. Resistance to chemotherapy can be present intrinsically before the administration of chemotherapy or it can develop during chemotherapy. The mechanisms of chemotherapy resistance in gastric cancer are complex and multifactorial. A variety of factors have been demonstrated to be involved in chemoresistance, including the reduced intracellular concentrations of drugs, alterations in drug targets, the dysregulation of cell survival and death signaling pathways, and interactions between cancer cells and the tumor microenvironment. This review focuses on the molecular mechanisms of chemoresistance in gastric cancer and on recent studies that have sought to overcome the underlying mechanisms of chemoresistance.

Citing Articles

Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.

Mora-Lagos B, Reyes M, Lobos-Gonzalez L, Del Campo M, Buchegger K, Zanella L Biol Res. 2025; 58(1):4.

PMID: 39827154 PMC: 11748569. DOI: 10.1186/s40659-024-00581-3.

EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.

Piper A, Penney C, Holliday J, Tincknell G, Ma Y, Napaki S Int J Mol Sci. 2024; 25(10).

PMID: 38791602 PMC: 11122469. DOI: 10.3390/ijms25105565.

Identification and characterization of ferroptosis-related genes in therapy-resistant gastric cancer.

Yu J, Li H, Huang C, Chen H Medicine (Baltimore). 2024; 103(20):e38193.

PMID: 38758860 PMC: 11098190. DOI: 10.1097/MD.0000000000038193.

Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development.

Shahid A, Santos S, Lin C, Huang Y Biomedicines. 2024; 12(3).

PMID: 38540176 PMC: 10967781. DOI: 10.3390/biomedicines12030563.

Role of microRNA-494 in tumor progression.

Maharati A, Akhlaghipour I, Taghehchian N, Yazdi Z, Moghbeli M Am J Transl Res. 2023; 15(11):6342-6361.

PMID: 38074823 PMC: 10703645.

References

Bhola P, Letai A . Mitochondria-Judges and Executioners of Cell Death Sentences. Mol Cell. 2016; 61(5):695-704. PMC: 4806554. DOI: 10.1016/j.molcel.2016.02.019. View

Tsujitani S, Saito H, Wakatsuki T, Ikeguchi M, Shirabe K, Morita M . Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today. 2011; 42(3):225-32. DOI: 10.1007/s00595-011-0062-z. View

Li V, Wong C, Chan T, Chan A, Zhao W, Chu K . Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005; 5:29. PMC: 1079799. DOI: 10.1186/1471-2407-5-29. View

Yu L, Dai N, Yu H, Sun L, Si J . Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells. Oncol Rep. 2010; 24(1):113-9. DOI: 10.3892/or_00000835. View

Zhang Y, Lu Q, Cai X . MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett. 2013; 587(18):3069-75. DOI: 10.1016/j.febslet.2013.06.058. View

Wagner A, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18):2903-9. DOI: 10.1200/JCO.2005.05.0245. View

Park J, Kramer B, Lai S, Goldstein L, Gazdar A . Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J Natl Cancer Inst. 1990; 82(3):193-8. DOI: 10.1093/jnci/82.3.193. View

Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S . miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008; 123(2):372-379. DOI: 10.1002/ijc.23501. View

Xu H, Xu L, Hao J, Qin C, Liu H . Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. J Int Med Res. 2010; 38(1):34-42. DOI: 10.1177/147323001003800104. View

10.

Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M . Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005; 117(3):376-80. DOI: 10.1002/ijc.21170. View

11.

Rocha G, Oliveira R, Kaplan M, Gattass C . 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. Eur J Pharmacol. 2014; 741:140-9. DOI: 10.1016/j.ejphar.2014.07.054. View

12.

Gao J, Tian Y, Zhang J . Overexpression of interferon regulatory factor 1 enhances chemosensitivity to 5-fluorouracil in gastric cancer cells. J Cancer Res Ther. 2012; 8(1):57-61. DOI: 10.4103/0973-1482.95175. View

13.

Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K . miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2013; 33(25):3267-76. DOI: 10.1038/onc.2013.297. View

14.

Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y . Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol. 2012; 18(45):6577-86. PMC: 3516204. DOI: 10.3748/wjg.v18.i45.6577. View

15.

Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N . NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003; 22(1):90-7. DOI: 10.1038/sj.onc.1206056. View

16.

Kim R, Ohi Y, Inoue H, Toge T . Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res. 2000; 19(6B):5393-8. View

17.

Cho H, Baek K, Park S, Kim I, Nam I, Choi Y . RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011; 311(1):48-56. DOI: 10.1016/j.canlet.2011.06.024. View

18.

de Oliveira J, Felipe A, Artigiani Neto R, Oshima C, Silva M, Forones N . Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients. Asian Pac J Cancer Prev. 2014; 15(16):6935-8. DOI: 10.7314/apjcp.2014.15.16.6935. View

19.

Isobe T, Aoyagi K, Koufuji K, Shirouzu K, Kawahara A, Kawahara A . Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer. Int J Clin Oncol. 2012; 18(2):293-304. DOI: 10.1007/s10147-012-0378-8. View

20.

Chung H, Gong S, Yoo N, Noh S, Kim J, Roh J . P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer. Yonsei Med J. 1996; 37(6):397-404. DOI: 10.3349/ymj.1996.37.6.397. View